Search
Dabigatran etexilate
go.drugbank.com/drugs/DB06695ApprovedInvestigational[A177463, A6970, L34675, L34680] Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom anticoagulation therapy is indicated. … [A177463] In contrast to warfarin, because its anticoagulant effects are predictable, lab monitoring is not necessary.[A177463] Dabigatran etexilate was approved by the FDA in 2010.[L6022]
Categories: Heterocyclic Compounds, 2-RingProducts: PRADAXA 110 MG SERT KAPSUL, 10 ADET, PRADAXA 75 MG SERT KAPSUL, 10 ADETRopinirole
go.drugbank.com/drugs/DB00268ApprovedInvestigationalIn 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome [A174547]. … It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: ROPINIROLO EG, ROPINIROLO EG STADAMetoclopramide
go.drugbank.com/drugs/DB01233ApprovedInvestigationalIt is available in the oral tablet form or in solution, and can also be administered through the intravenous route.[T683] Metoclopramide was initially approved by the FDA in 1980.[A184922] … [L8417] One unique property of this drug is that it does not increase gastric acid secretion.
Synonyms: 2-methoxy-4-amino-5-chloro-N,N-(dimethylaminoethyl)benzamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)-o-anisamideMixtures: PCP 100 Kit, ESPAVEN MDFish oil
go.drugbank.com/drugs/DB13961ApprovedInvestigationalNutraceuticalHowever, prescription-only fish oil products are sometimes prescribed for individuals who demonstrate severe (>= 500 mg/dL) hypertriglyceridemia [FDA Label]. … Such fish oils are available in both non-prescription and prescription-only varieties at different concentrations.
Mixtures: OGAMIX(Evening primrose oil 500 mg, Lecithin oil 500 mg, Fish oil 125 mgand Vitamin E 10 mg Soft Gelatin Capsule), SMOFlipid 200 mg/ml Emulsion zur InfusionCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesPanitumumab
go.drugbank.com/drugs/DB01269ApprovedInvestigationalThis drug is an antineoplastic agent. Panitumumab was granted FDA approval on 27 September 2006.[L17663]
Products: Vectibix Concentrate for Solution for Infusion 100 mg/vial, VECTIBIX® 20 MG/ MLDacarbazine
go.drugbank.com/drugs/DB00851ApprovedInvestigationalAn antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). … Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.
Synonyms: 4-(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide, 4-(dimethyltriazeno)imidazole-5-carboxamideCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesNandrolone decanoate
go.drugbank.com/drugs/DB08804ApprovedIllicitInvestigational[A233849] Nandrolone decanoate was granted FDA approval on 5 October 1962.[L32564] … [A233789,A233849,L32564,L9464] The process for creating esters of [nandrolone] was patented in Spain in 1959[L33244] and in 1960, it was described as having a long duration of action and strong anabolic
Products: DECA - DURABOLIN® 50 MG, Deca-Durabolin 50 mg/ml InjektionslösungAlteplase
go.drugbank.com/drugs/DB00009ApprovedInvestigationalAlteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent.[L43125] It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. … [A252345,L43125] It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI).
Mixtures: Activase RT-PA, Lysatec RT - PaSynonyms: t-PA, rt-PALacidipine
go.drugbank.com/drugs/DB09236ApprovedIt is available as once-daily oral tablets containing 2 or 4 mg of the active compound commonly marketed as Lacipil or Motens. It is not currently FDA-approved. … In randomised, well-controlled trials, administration of daily single-dose lacidipine ranging from 2-6 mg demonstrated comparable antihypertensive efficacy similar to that of other long-acting dihydropyridine
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: LACIDIPINA EG, LACIPIL 4 MG FILM KAPLI TABLET, 28 ADETPirfenidone
go.drugbank.com/drugs/DB04951ApprovedInvestigational[A251370] It is an antifibrotic agent with anti-inflammatory and antioxidant properties [A251370] that is used to treat idiopathic pulmonary fibrosis (IPF),[L26801] which is a chronic, progressive form … [A251370] While its mechanism of action is not yet fully understood, pirfenidone is proposed to primarily regulate tumor necrosis factor (TNF) pathways and modulate cellular oxidation.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsProducts: PIRFENIDONE EG, ESBRİET 267 MG FİLM KAPLI TABLET, 21 TABLET